A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
Annals of Clinical and Translational Neurology · 2023
DOI: 10.1002/acn3.51863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2023. Verfasst von Mark Monane und 15 weiteren Autor:innen. Beteiligte Einrichtung: C2N Diagnostics, LLC, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (PrecivityAD® blood test) in symptomatic patients evaluated for Alzheimer's disease (AD) or other causes of cognitive decline.
Methods
The Quality Improvement and Clinical Utility PrecivityAD Clinician Survey (QUIP I, ClinicalTrials.gov Identifier: NCT05477056) was a prospective, single‐arm cohort study among 366 patients evaluated by neurologists and other cognitive specialists. Participants underwent blood biomarker testing and received an amyloid probability score (APS), indicating the likelihood of a positive result on an amyloid positron emission tomography (PET) scan. The primary study outcomes were appropriateness of patient selection as well as result interpretation associated with PrecivityAD blood testing.
Results
A 95% (347/366) concordance rate was noted between clinicians' patient selection and the test's intended use criteria. In the final analysis including these 347 patients (median age 75 years, 56% women), prespecified test result categories incorporated 133 (38%) low APS, 162 (47%) high APS, and 52 (15%) intermediate APS patients. Clinicians' pretest and posttest AD diagnosis probability changed from 58% to 23% in low APS patients and 71% to 89% in high APS patients ( p < 0.0001). Anti‐AD drug therapy decreased by 46% in low APS patients ( p < 0.0001) and increased by 57% in high APS patients ( p < 0.0001).
Interpretation
These findings demonstrate the clinical utility of the PrecivityAD blood test in clinical care and may have added relevance as new AD therapies are introduced.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- C2N Diagnostics, LLC, St. Louis, Missouri, USA.
- Department of Psychiatry & Behavioral Sciences, Duke University, Durham, North Carolina, USA.
- Washington University School of Medicine, St. Louis, Missouri, USA.
- Georgetown University School of Medicine, Washington, DC, USA.
- Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.
- Department of Neurology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
ORCID-Profile: Mark Monane, Ilana Fogelman
Zitieren
APA
Monane, M., Johnson, K. G., Snider, B. J., Turner, R. S., Drake, J. D., Maraganore, D. M., Bicksel, J. L., Jacobs, D. H., Ortega, J. L., Henderson, J., Jiang, Y., Huang, S., Coppinger, J., Fogelman, I., West, T., & Braunstein, J. B. (2023). A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51863
Vancouver
Monane M, Johnson KG, Snider BJ, Turner RS, Drake JD, Maraganore DM, et al. A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51863
BibTeX
@article{Monane2023,
author = {Monane, Mark and Johnson, Kim G and Snider, B Joy and Turner, Raymond S and Drake, Jonathan D and Maraganore, Demetrius M and Bicksel, James L and Jacobs, Daniel H and Ortega, Julia L and Henderson, Joni and Jiang, Yan and Huang, Shuguang and Coppinger, Justine and Fogelman, Ilana and West, Tim and Braunstein, Joel B},
title = {A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
doi = {10.1002/acn3.51863}
}
EUVIMED